Search
favipiravir (Avigan)
Indications:
- used to treat influenza in Japan
- Ebola virus (Ebola hemorrhagic fever)
- effective in treating some Ebola-infected patients in a preliminary study
- may reduce mortality in patients with low-to-moderate levels of Ebola virus in the blood (15% vs 30%)
- no benefit in patients with high viral levels
- may be useful for post-exposure prophylaxis [2]
- approved in Russia for treatment of Covid-19 [3]
Mechanism of action:
- RNA polymerase inhibitor
General
antiviral agent
Database Correlations
PUBCHEM correlations
References
- Young K, Sofair A, Chavey WE
Favipiravir Shows Some Promise in Early Ebola Study
Physician's First Watch, Feb 6, 2015
David G. Fairchild, MD, MPH, Editor-in-Chief
Massachusetts Medical Society
http://www.jwatch.org
- Jacobs M et al
Post-exposure prophylaxis against Ebola virus disease with
experimental antiviral agents: a case-series of health-care
workers.
Lancet Infectious Disease. Aug 25, 2015
PMID: 26321189
http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2815%2900228-5/abstract
- Bergman SJ
COVID-19 Treatment: Investigational Drugs and Other Therapies.
Mesdcape. August 18, 2021
https://emedicine.medscape.com/article/2500116-overview